Moderna CEO Stéphane Bancel Halts Investment in Vaccine Phase 3 Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Should l Buy MRNA?
Source: seekingalpha
- Vaccine Development Halted: Moderna CEO Stéphane Bancel announced that the company will not fund further late-stage vaccine development due to U.S. government pushback against immunizations, making future Phase 3 studies unlikely.
- Market Access Barriers: Bancel highlighted that lack of access to the U.S. market, regulatory delays, and a smaller market size have rendered vaccine investments unviable, significantly impacting the company's strategic direction.
- Public Health Impact: Under the Trump administration, the CDC has narrowed COVID-19 vaccine recommendations, preventing many effective vaccines from advancing to Phase 3 trials, which Bancel lamented, emphasizing their importance for public health.
- Strategic Shift: Moderna is shifting its focus to cancer and heart disease research, acknowledging that while many vaccines could have a significant public health impact, policy constraints prevent the company from advancing these projects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 50.110
Low
17.00
Averages
32.47
High
63.00
Current: 50.110
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Moderna's Stock Soars 72% in Q1, Leading Healthcare Sector
- Shift in Investor Sentiment: Moderna's stock surged 72% in Q1, making it the best-performing healthcare stock in the S&P 500, reflecting a renewed investor confidence in its growth potential after a period of declining stock performance due to reduced vaccine demand.
- Diversification Strategy: The company is transitioning from a coronavirus vaccine manufacturer to a multi-faceted biotech firm, with plans to launch a flu vaccine alongside existing COVID-19 and RSV vaccines, which are expected to fund its oncology and rare disease initiatives.
- Revenue Growth Expectations: Moderna anticipates that seasonal vaccines will drive up to 10% revenue growth this year, and by cutting costs by 30% since 2024, it achieved over $2 billion in savings last year, enhancing its financial stability.
- Clinical Trial Progress: The ongoing collaboration with Merck on the mRNA-4157 project includes eight phase 2 and phase 3 trials, and successful results could significantly boost its competitive position in the oncology market, further solidifying its market presence.
See More
Moderna's Stock Soars 72% in Q1, Leading Healthcare Sector
- Outstanding Stock Performance: Moderna's stock surged 72% in Q1, making it the best performer among healthcare companies in the S&P 500, indicating a significant shift in investor sentiment amidst a broader market aversion to AI and growth stocks.
- Revenue Growth Expectations: The company anticipates seasonal vaccines could deliver up to 10% revenue growth, with its new vaccine pipeline, including flu and norovirus vaccines, expected to fund its oncology and rare disease programs, thereby enhancing its market competitiveness.
- Significant Cost Control: Moderna has reduced costs by 30% since 2024, achieving over $2 billion in savings last year, which provides robust financial support for future R&D and market expansion efforts.
- Notable Oncology Progress: Moderna is conducting eight phase 2 and phase 3 clinical trials in collaboration with Merck, particularly for melanoma, with phase 3 data expected this year, which could further solidify its position in the oncology market.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Healthcare Sector Faces Significant Decline Amid Market Challenges
- Quarterly Performance Decline: In Q1 2026, the Health Care Select Sector SPDR Fund (XLV) fell by 5.29%, slightly underperforming the S&P 500 Index's 4.63% drop, reflecting the negative impact of persistent inflation and oil supply shocks on market sentiment.
- Notable Sector Divergence: Among the 11 S&P 500 sectors, the Energy Select Sector (XLE) surged 37.02% year-to-date, while the Health Care Equipment & Services sector declined by 12.32%, highlighting a significant divergence between defensive sectors and traditional bull market leaders like Technology and Financials.
- Severe Rating Downgrade: XLV's Seeking Alpha Quant Rating plummeted from 'Buy' (3.59/5) to 'Sell' (1.3/5), primarily due to a collapse in momentum from B to D, even as liquidity remained strong at A+, indicating a weakening investor confidence in the fund.
- Continued Fund Inflows: Despite a challenging quarterly return of -5.29%, the XLV ETF recorded net inflows of $1.11 billion in Q1 2026, suggesting that investor conviction in the healthcare sector remained surprisingly resilient during this period.
See More
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Moderna's Stock Soars 72% in Q1, Leading Healthcare Sector
- Shift in Investor Sentiment: Moderna's stock surged 72% in Q1, making it the best-performing healthcare stock in the S&P 500, reflecting a renewed investor confidence in its growth potential after a period of declining stock performance due to reduced vaccine demand.
- Diversification Strategy: The company is transitioning from a coronavirus vaccine manufacturer to a multi-faceted biotech firm, with plans to launch a flu vaccine alongside existing COVID-19 and RSV vaccines, which are expected to fund its oncology and rare disease initiatives.
- Revenue Growth Expectations: Moderna anticipates that seasonal vaccines will drive up to 10% revenue growth this year, and by cutting costs by 30% since 2024, it achieved over $2 billion in savings last year, enhancing its financial stability.
- Clinical Trial Progress: The ongoing collaboration with Merck on the mRNA-4157 project includes eight phase 2 and phase 3 trials, and successful results could significantly boost its competitive position in the oncology market, further solidifying its market presence.
See More
Moderna's Stock Soars 72% in Q1, Leading Healthcare Sector
- Outstanding Stock Performance: Moderna's stock surged 72% in Q1, making it the best performer among healthcare companies in the S&P 500, indicating a significant shift in investor sentiment amidst a broader market aversion to AI and growth stocks.
- Revenue Growth Expectations: The company anticipates seasonal vaccines could deliver up to 10% revenue growth, with its new vaccine pipeline, including flu and norovirus vaccines, expected to fund its oncology and rare disease programs, thereby enhancing its market competitiveness.
- Significant Cost Control: Moderna has reduced costs by 30% since 2024, achieving over $2 billion in savings last year, which provides robust financial support for future R&D and market expansion efforts.
- Notable Oncology Progress: Moderna is conducting eight phase 2 and phase 3 clinical trials in collaboration with Merck, particularly for melanoma, with phase 3 data expected this year, which could further solidify its position in the oncology market.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Healthcare Sector Faces Significant Decline Amid Market Challenges
- Quarterly Performance Decline: In Q1 2026, the Health Care Select Sector SPDR Fund (XLV) fell by 5.29%, slightly underperforming the S&P 500 Index's 4.63% drop, reflecting the negative impact of persistent inflation and oil supply shocks on market sentiment.
- Notable Sector Divergence: Among the 11 S&P 500 sectors, the Energy Select Sector (XLE) surged 37.02% year-to-date, while the Health Care Equipment & Services sector declined by 12.32%, highlighting a significant divergence between defensive sectors and traditional bull market leaders like Technology and Financials.
- Severe Rating Downgrade: XLV's Seeking Alpha Quant Rating plummeted from 'Buy' (3.59/5) to 'Sell' (1.3/5), primarily due to a collapse in momentum from B to D, even as liquidity remained strong at A+, indicating a weakening investor confidence in the fund.
- Continued Fund Inflows: Despite a challenging quarterly return of -5.29%, the XLV ETF recorded net inflows of $1.11 billion in Q1 2026, suggesting that investor conviction in the healthcare sector remained surprisingly resilient during this period.
See More
